THE EFFECT OF INTRAVENOUS METFORMIN ON GLUCOSE-METABOLISM DURING HYPERGLYCEMIA IN TYPE-2 DIABETES

被引：81

作者：

SUM, CF ^{[1
]}

WEBSTER, JM ^{[1
]}

JOHNSON, AB ^{[1
]}

CATALANO, C ^{[1
]}

COOPER, BG ^{[1
]}

TAYLOR, R ^{[1
]}

机构：

[1] UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND

来源：

DIABETIC MEDICINE | 1992年 / 9卷 / 01期

关键词：

METFORMIN; INSULIN SENSITIVITY; GLUCOSE DISPOSAL HEPATIC GLUCOSE PRODUCTION; TYPE-2; DIABETES;

D O I：

10.1111/j.1464-5491.1992.tb01716.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A stepped intravenous metformin infusion was used in conjunction with the hyperglycaemic clamp technique to study the dose-response relationship of plasma metformin concentration with hepatic glucose production and peripheral glucose disposal in nine patients with Type 2 diabetes. The study was of double-blind crossover design, using NaCl infusion as control. Plasma metformin concentrations spanning the therapeutic range (1.64 +/- 0.13 mg l-1 and 6.57 +/- 0.61 mg l-1) were achieved. No differences in peripheral glucose disposal were demonstrated when compared with NaCl infusion (3.4 +/- 0.1 vs 3.6 +/- 0.2 (+/- SE) mg kg-1 min-1 and 3.4 +/- 0.2 vs 3.3 +/- 0.2 mg kg-1 min-1, respectively). There was also no difference in basal hepatic glucose production during metformin and NaCl infusion (2.7 +/- 0.3 vs 2.8 +/- 0.2 mg kg-1 min-1). No acute effect of metformin on hepatic glucose production or peripheral glucose disposal was observed, implying that a chronic persistent effect is more important in these respects than immediate effects consequent upon changes in plasma drug level.

引用

页码：61 / 65

页数：5

共 20 条

[1] Jackson RA, Hawa MI, Jaspan BJ, Et al., Mechanism of metformin action in non‐insulin‐dependent diabetes, Diabetes, 36, pp. 632-640, (1987)
[2] Sterne J., Junien JL., Metformin: pharmacological mechanism of the antidiabetic and antilipidic effects and clinical consequences, Royal Society of Medicine International Congress and Symposium, 48, pp. 3-16, (1981)
[3] Bailey CJ, Nattrass M., Treatment—metformin, Non‐insulin‐dependent Diabetes. Baillière's Clinical Endocrinology and Metabolism, 2-2, pp. 455-476, (1988)
[4] Pentikainen PJ, Neuvonen PJ, Penttila A., Pharmokinetics of metformin after intravenous and oral administration to man, Eur J Clin Pharmacol, 16, pp. 195-202, (1979)
[5] Tucker GT, Casey C., Phillips PJ, Connor H., Ward JD, Woods HF., Metformin kinetics in healthy subjects and in patients with diabetes mellitus, Br J Clin Pharmacol, 12, pp. 235-246, (1981)
[6] Pentikainen PJ., Bioavailability of metformin: Comparison of solution, rapidly dissolving tablet, and three sustained release products, Int J Clin Pharmacol Therapy Toxicol, 24, pp. 213-220, (1986)
[7] Bailey CJ., Metformin revisited. Its actions and indications for use, Diabetic Med, 5, pp. 315-320, (1988)
[8] Sterne J., Pharmacology and mode of action of the hypoglycaemic guanidine derivatives, Oral Hypoglycaemic Agents, pp. 193-245, (1969)
[9] Barzilai N., Simonson D., Mechanism of metformin action in NIDDM (Abstract), Diabetes, 7, (1988)
[10] Nosadini R., Avogaro A., Trevisan R., Effect of metformin on insulin‐stimulated glucose turnover and insulin binding to receptors in type II diabetes, Diabetes Care, 10, pp. 62-67, (1987)

← 1 2 →